Table 3. Comparison of neonatal morbidities and therapies.
| Period I (1996–1999) n=117 | Period II (2000–2003) n=105 | P-value | |
|---|---|---|---|
| Neonatal therapies | |||
| Surfactant, n (%) | 101 (86) | 103 (98) | 0.001 |
| Indomethacin therapy, n (%)a | 65 (56) | 84 (80) | <0.001 |
| Surgical ligation of patent ductus arteriosus, n (%) | 31 (27) | 42 (40) | 0.032 |
| Postnatal steroid therapy, n (%) | 88 (75) | 30 (29) | <0.001 |
| Days postnatal steroids (median, range)b | 25 (2–102) | 8 (2–39) | <0.001 |
| Duration of ventilator dependence (median days, range) | 36 (2–86) | 40 (3–180) | 0.027 |
| Duration of oxygen dependence (median days, range)c | 105 (63–688) | 100 (64–727) | 0.357 |
| Neonatal morbidity | |||
| Sepsis, n (%) | 59 (50) | 55 (52) | 0.771 |
| Patent ductus arteriosus, n (%) | 78 (67) | 78 (74) | 0.215 |
| Necrotizing enterocolitis, n (%) | 6 (5) | 8 (8) | 0.446 |
| Indirect hyperbilirubinemia, n (%)d | 11 (9) | 12 (11) | 0.621 |
| Periventricular hemorrhage, n (%) | 51 (44) | 29 (28) | 0.013 |
| Periventricular leukomalacia, n (%) | 10 (9) | 7 (7) | 0.599 |
| Ventriculomegaly at discharge, n (%) | 16 (14) | 8 (8) | 0.147 |
| Severe cranial ultrasound abnormality, n (%)e | 30 (26) | 14 (13) | 0.022 |
a
Prophylaxis or treatment.
b
For those who received postnatal steroids.
c
Including oxygen given after discharge in the home.
d
Bilirubin >10 mg per 100 ml.
e
Includes grades III–IV intraventricular hemorrhage, periventricular leukomalacia and/or ventriculomegaly at discharge.